T-CELL LYMPHOMA
Clinical trials for T-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new T-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for T-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for Hard-to-Treat lymphoma: targeted drug shows promise even when marker levels are low
Disease control CompletedThis study tested a drug called brentuximab vedotin in 23 people with a type of blood cancer (T-cell lymphoma) that had stopped responding to or returned after previous chemotherapy. The drug is designed to seek out and kill cancer cells that have a specific marker called CD30, e…
Matched conditions: T-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Deepa Jagadeesh • Aim: Disease control
Last updated May 26, 2026 06:52 UTC
-
New hope for tough blood cancers: experimental drug PRT2527 tested in early trial
Disease control CompletedThis early-stage study tested a new drug called PRT2527, alone or combined with other medicines (zanubrutinib or venetoclax), in 86 people with blood cancers that returned or didn't respond to standard treatments. The main goals were to check safety, find the best dose, and see i…
Matched conditions: T-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Prelude Therapeutics • Aim: Disease control
Last updated May 22, 2026 14:05 UTC
-
CRISPR-Engineered immune cells take on tough blood cancers
Disease control CompletedThis study tested a new treatment called CTX131 for adults with certain blood cancers (T cell lymphoma, B cell lymphoma, or acute myeloid leukemia) that came back or didn't respond to standard therapy. CTX131 uses CRISPR gene editing to create donor immune cells that target and a…
Matched conditions: T-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: CRISPR Therapeutics • Aim: Disease control
Last updated May 22, 2026 14:01 UTC
-
New hope for rare skin cancer: targeted drug shows promise in chinese patients
Disease control CompletedThis study looked at the long-term side effects and effectiveness of a drug called brentuximab vedotin in 10 Chinese adults with a rare type of skin lymphoma (CD30-positive cutaneous T-cell lymphoma). Participants received the drug through a vein every 3 weeks for up to 16 cycles…
Matched conditions: T-CELL LYMPHOMA
Phase: PHASE4 • Sponsor: Takeda • Aim: Disease control
Last updated May 22, 2026 13:50 UTC